Log In Get Started
Press Releases June 3, 2026 02:14 AM

RENEWAL OF THE AGREEMENT BETWEEN SCUDERIA FERRARI HP AND CHARLES LECLERC

Ferrari extends contract with star driver Charles Leclerc for multiple F1 seasons

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
RACE

Ferrari N.V. announces a multi-year renewal agreement with Charles Leclerc to remain an official driver for Scuderia Ferrari HP in upcoming Formula 1 World Championship seasons, securing key talent for the racing team.

RENEWAL OF THE AGREEMENT BETWEEN SCUDERIA FERRARI HP AND CHARLES LECLERC
RACE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Charles Leclerc's contract with Scuderia Ferrari HP has been extended for multiple upcoming F1 seasons.
  • This renewal strengthens Ferrari's driver lineup for the competitive Formula 1 World Championship.
  • Ferrari N.V. continues to invest in its motorsports division, impacting brand visibility and marketing in the automotive and sports sectors.

Maranello (Italy), June 3, 2026 - Ferrari N.V. (NYSE/EXM: RACE) announces the multi-year renewal of the agreement between Scuderia Ferrari HP and Charles Leclerc.

In the upcoming seasons of Formula 1 World Championship, Leclerc will continue to compete as an official driver for the Maranello team.

Attachment

  • FNV PR CL June 3 2026 ENG

Risks

  • Performance risks remain as future race outcomes could impact Ferrari's brand and sponsorship attractiveness, influencing automotive and sports marketing sectors.
  • Potential external factors like regulatory changes in Formula 1 or driver injuries could affect the team's competitiveness, impacting the automotive and entertainment industries.
  • Market volatility affecting Ferrari's overall stock performance could influence investor sentiment despite the contract renewal.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026